Q4 2025 earnings call: ivonescimab Phase III updates, FDA PDUFA timeline, interim PFS in Q2 2026, cash position—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results